Pluripotent stem cells have infinite capacity; they can self-renew indefinitely and differentiate to any cell in the body, given the right conditions. Directed differentiation of human pluripotent stem cells (hPSCs) towards specific cell types, through defined culture conditions, provides significant promise in the field of regenerative medicine, drug discovery, and disease modelling.
Growth factors and cytokines are often used as interchangeable terms to describe the proteins involved with cell signaling. But, what is the difference between growth factors, cytokines and other cell signalers like hormones?
This month: on-demand webinar, can R-spondin1 recombinant protein replace conditioned media? and enter our photo competition
this month: TGFbeta3 launched, photo competition now open and are endoderm implants the future of medicine?
In this months pep talk we explore why quality isn't just about purity and a product spotlight on BMP-4 lot comparibility.
On Friday, 11th February, it’s International Day of Women and Girls in Science 2022. To celebrate, I’d like to give a big shout-out to people of all genders who champion gender equality in science and inspire the next generations of scientists, thank you!
Happy New Year! It’s five years since Marko and I founded Qkine, the time has flown. Highlights have been the wonderful feedback we’ve had from customers and launching innovative products such as the first true animal-free TGFβ1, tag-free thermostable FGF2-G3, and demonstrating the efficacy of HGF NK1 in hepatocyte differentiation.
There has been an impressive drive towards innovation in stem cell protocols this year. As 2021 comes to a close, we reflect on the highlights for stem cell science over the year. It was great to see new culture media, such as B8 and “Beefy-9”, published, developments in cultivated meat science hit the news and iPSC-based therapies edge closer to the clinic. Reproducibility remains the underlying theme, and indeed requirement, for maximising the impact of these wonderful developments and at Qkine we’ll continue to do everything we can to help in 2022.
There has been an impressive drive towards innovation in stem cell protocols this year. As 2021 comes to a close, we reflect on the highlights for stem cell science over the year. It was great to see new culture media, such as B8 and “Beefy-9”, published, developments in cultivated meat science hit the news and iPSC-based therapies edge closer to the clinic. Reproducibility remains the underlying theme, and indeed requirement, for maximising the impact of these wonderful developments and at Qkine we’ll continue to do everything we can to help in 2022.
October update celebrating the launch of hyperstable FGF2-G3 for media optimisation, new media recipe quick reference resources for organoid researchers and the launch of animal-free OSM, which completes the hepatocyte differentiation growth factor set. Not forgetting us becoming an ISO9001: 2015 certified manufacturer!
© 2024 Qkine Ltd. Company number 10470662 registered in England and Wales. All rights reserved
